Unintentional weight loss and weight loss in those with a body mass index already in the normal range were particularly associated with risk of pancreatic cancer among patients with recent-onset diabetes, a study found.
A pooled analysis of three randomized clinical trials found reductions in major adverse cardiac or cerebrovascular events after percutaneous coronary intervention (PCI) at 3.9-year follow-up only in patients with low-density lipoprotein (LDL)
In a systematic review and meta-analysis, no difference was seen between high- and low-dose sodium-glucose cotransporter-2 (SGLT-2) inhibitors in overall safety or specific safety outcomes, other than a mild increased risk for adverse events with
An industry-sponsored phase 3 trial found statistically significant improvements in HbA1c level among patients with type 2 diabetes who had inadequate glycemic control on insulin glargine and were randomly assigned to subcutaneous tirzepatide once
A meta-analysis of six studies found that patient-led titration was associated with lower HbA1c and fasting plasma glucose levels than physician-led titration, although hypoglycemia risk and body weight were slightly higher.
Patients with type 2 diabetes who had no diabetes-related polyneuropathy, diabetes-related polyneuropathy with pain, and diabetes-related polyneuropathy without pain were compared in an industry-funded retrospective study.
A new consensus report urged clinicians to discuss self-management education and support with all diabetes patients and provide referrals at four critical points in care, including diagnosis.
The study highlights the role of depression as specific risk factor for death in patients with diabetes after major LEA and suggests including its definition and management in strategies to reduce
On average during six influenza seasons, the protective effect of the vaccine in preventing influenza hospitalization was 46% for current-season vaccination and 44% for vaccination in prior seasons only, a Spanish study found.
Mean out-of-pocket spending for all care among a national sample of insured patients with type 1 diabetes was nearly $2,500 in 2018, according to one study, while a second study found that commercially insured patients' out-of-pocket insulin costs